Ian C Brett

Summary

Affiliation: State University of New York
Country: USA

Publications

  1. ncbi request reprint Variation in the divalent cation requirements of influenza a virus N2 neuraminidases
    Bert E Johansson
    Department of Pediatrics, Division of Critical Care Medicine, Weill Medical College of Cornell University, 525 East 68th St, Box 437, New York, NY 10021, USA
    J Biochem 134:345-52. 2003
  2. ncbi request reprint Immunization against influenza A virus: comparison of conventional inactivated, live-attenuated and recombinant baculovirus produced purified hemagglutinin and neuraminidase vaccines in a murine model system
    Ian C Brett
    Department of Pediatrics, Division of Pediatric Critical Care Medicine, Weill Medical College of Cornell University, 525 East 68th Street, New York, NY 10021, USA
    Virology 339:273-80. 2005
  3. ncbi request reprint Variation in the divalent cation requirements of influenza A virus N1 neuraminidases
    Ian C Brett
    Department of Pediatrics, Division of Critical Care Medicine, Weill Medical College of Cornell University, 525 East 68th St, New York, NY 10021, USA
    J Biochem 139:439-47. 2006
  4. ncbi request reprint An inactivated subvirion influenza A (H5N1) vaccine
    Bert E Johansson
    N Engl J Med 354:2724-5; author reply 2724-5. 2006
  5. ncbi request reprint Changing perspective on immunization against influenza
    Bert E Johansson
    Innovation Sciences, Armonk, NY 10504, USA
    Vaccine 25:3062-5. 2007
  6. ncbi request reprint Recombinant influenza B virus HA and NA antigens administered in equivalent amounts are immunogenically equivalent and induce equivalent homotypic and broader heterovariant protection in mice than conventional and live influenza vaccines
    Bert E Johansson
    Innovation Sciences, Armonk, New York 10504, USA
    Hum Vaccin 4:420-4. 2008

Collaborators

  • Bert E Johansson

Detail Information

Publications6

  1. ncbi request reprint Variation in the divalent cation requirements of influenza a virus N2 neuraminidases
    Bert E Johansson
    Department of Pediatrics, Division of Critical Care Medicine, Weill Medical College of Cornell University, 525 East 68th St, Box 437, New York, NY 10021, USA
    J Biochem 134:345-52. 2003
    ....
  2. ncbi request reprint Immunization against influenza A virus: comparison of conventional inactivated, live-attenuated and recombinant baculovirus produced purified hemagglutinin and neuraminidase vaccines in a murine model system
    Ian C Brett
    Department of Pediatrics, Division of Pediatric Critical Care Medicine, Weill Medical College of Cornell University, 525 East 68th Street, New York, NY 10021, USA
    Virology 339:273-80. 2005
    ..These studies suggest that vaccines immunogenic for both HA and NA offer an increased level of protection from influenza...
  3. ncbi request reprint Variation in the divalent cation requirements of influenza A virus N1 neuraminidases
    Ian C Brett
    Department of Pediatrics, Division of Critical Care Medicine, Weill Medical College of Cornell University, 525 East 68th St, New York, NY 10021, USA
    J Biochem 139:439-47. 2006
    ..Selection of vaccine strains must include analysis of antigenic changes, but also enzymatic studies and determination of the requirement of divalent cations to maintain immunogenicity and activity during production...
  4. ncbi request reprint An inactivated subvirion influenza A (H5N1) vaccine
    Bert E Johansson
    N Engl J Med 354:2724-5; author reply 2724-5. 2006
  5. ncbi request reprint Changing perspective on immunization against influenza
    Bert E Johansson
    Innovation Sciences, Armonk, NY 10504, USA
    Vaccine 25:3062-5. 2007
    ..Alternative production technologies such as recombinant baculovirus and yeast should be explored to decrease vaccine production times...
  6. ncbi request reprint Recombinant influenza B virus HA and NA antigens administered in equivalent amounts are immunogenically equivalent and induce equivalent homotypic and broader heterovariant protection in mice than conventional and live influenza vaccines
    Bert E Johansson
    Innovation Sciences, Armonk, New York 10504, USA
    Hum Vaccin 4:420-4. 2008
    ..This report demonstrates with influenza B virus, in a side-by-side comparison with CIV and LAIV in a murine model system the superiority of vaccines containing immunogenic NA over currently approved CIV and LAIV vaccines...